Curasight presented promising phase II results from an investigator initiated phase II stu with uTRACE in prostate cancer. About two years later, the company now secures a first license deal for its theranostic platform.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
11.5 DKK | +13.86% | +20.55% | -35.21% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-35.21% | 33.27M | |
+49.36% | 54.63B | |
-4.89% | 39.92B | |
+37.55% | 38.82B | |
+15.30% | 26.86B | |
-12.56% | 26.22B | |
-21.87% | 18.78B | |
+25.85% | 12.21B | |
+1.98% | 12.16B | |
+26.66% | 11.94B |
- Stock Market
- Equities
- CURAS Stock
- News Curasight A/S
- Curasight Secures Global License Agreement for Utrace in Prostate Cancer